{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T07:50:36Z","timestamp":1649058636975},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T00:00:00Z","timestamp":1345075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s11899-012-0133-2","type":"journal-article","created":{"date-parts":[[2012,8,15]],"date-time":"2012-08-15T05:10:11Z","timestamp":1345007411000},"page":"221-227","source":"Crossref","is-referenced-by-count":4,"title":["Biological Therapy Doublets: Pairing Rituximab with Interferon, Lenalidomide, and Other Biological Agents in Patients with Follicular Lymphoma"],"prefix":"10.1007","volume":"7","author":[{"given":"Eva","family":"Kimby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,16]]},"reference":[{"issue":"5 Suppl 5","key":"133_CR1","first-page":"75","volume":"20","author":"SJ Horning","year":"1993","unstructured":"Horning SJ. Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas. Semin Oncol. 1993;20(5 Suppl 5):75\u201388.","journal-title":"Semin Oncol"},{"issue":"9383","key":"133_CR2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516\u201322.","journal-title":"Lancet"},{"key":"133_CR3","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417\u201323.","journal-title":"Blood"},{"key":"133_CR4","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone \u2500 results of a prospective randomised study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2005;106:3725\u201332.","journal-title":"Blood"},{"key":"133_CR5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"\u2022\u2022 Salles G, Seymour J-F, Offner F, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351. Salles et al 2011. This large randomized trial shows a significant benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy induction regimen.","journal-title":"Lancet"},{"key":"133_CR6","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustin plus Riutximab is superior in respect of progression free survival and CR rate when compared to CHOP plus Rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the STIL. Abstracts of the 2009 Annual Meeting of the American Society of Hematology Dec 5, 2009 New Orleans, Louisiana. Abstract 405.","DOI":"10.1182\/blood.V114.22.405.405"},{"key":"133_CR7","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustin plus Riutximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. Abstracts of the 2012 Annual Meeting of the American Society of Clinical Oncology; June 1\u20135, 2012; Chicago. Illinois. Abstract 3.","DOI":"10.1200\/jco.2012.30.18_suppl.3"},{"issue":"10","key":"133_CR8","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295\u2013301.","journal-title":"Blood"},{"issue":"17","key":"133_CR9","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Oers van","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853\u20138.","journal-title":"J Clin Oncol"},{"key":"133_CR10","unstructured":"A phase 3 open\u2010label randomized study to compare the efficacy and safety of Rituximab plus lenalidomide (CC\u20105013) versus Rituximab plus chemotherapy followed by Rituximab in subjects with previously untreated follicular lymphoma. The \u201cRELEVANCE\u201d trial (Rituximab Lenalidomide Versus Any Chemotherapy). Sponsor: Celgene Corporation Collaborator: the lymphoma academic research organisation. ClinicalTrials.gov Identifier: NCT01476787."},{"issue":"21","key":"133_CR11","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159\u201369.","journal-title":"N Engl J Med"},{"key":"133_CR12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1078-0432.CCR-06-1734","volume":"13","author":"BE Wahlin","year":"2007","unstructured":"Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res. 2007;13:388\u201397.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"133_CR13","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","volume":"108","author":"J Carreras","year":"2006","unstructured":"Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108(9):2957\u201364.","journal-title":"Blood"},{"issue":"9","key":"133_CR14","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","volume":"27","author":"J Carreras","year":"2009","unstructured":"Carreras J, Lopez-Guillermo A, Roncador G, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009;27(9):1470\u20136.","journal-title":"J Clin Oncol"},{"key":"133_CR15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","volume":"16","author":"BE Wahlin","year":"2010","unstructured":"Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1\u2013positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16:637\u201350.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"133_CR16","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","volume":"106","author":"P Farinha","year":"2005","unstructured":"Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106(6):2169\u201374. 15.","journal-title":"Blood"},{"issue":"16","key":"133_CR17","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","volume":"113","author":"SP Hilchey","year":"2009","unstructured":"\u2022\u2022 Hilchey SP, Hyrien O, Mosmann TR, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab. Blood. 2009;113(16):3809\u201312. The response against the immunoglobulin expressed by the follicular lymphoma cells before and after rituximab monotherapy showed an increase in FL idiotype-specific T cells providing \"proof of principle\" for the ability of passive immunotherapy with rituximab to elicit an active FL-specific cellular response (vaccinal effect).","journal-title":"Blood"},{"key":"133_CR18","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u201333.","journal-title":"J Clin Oncol"},{"key":"133_CR19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LT Piro","year":"1999","unstructured":"Piro LT, White CA, Grillo-L\u00f3pez AJ, et al. Extended rituximab (anti CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol. 1999;10:655\u201361.","journal-title":"Ann Oncol"},{"key":"133_CR20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101\u20136.","journal-title":"Blood"},{"key":"133_CR21","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103:4416\u201323.","journal-title":"Blood"},{"issue":"29","key":"133_CR22","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"\u2022\u2022 Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol. 2010;28(29):4480\u20134. Of considerable interest. In total 45 % of previously untreated patients responding to rituximab single induction (four weekly infusions) and receiving prolonged treatment (four additional doses of rituximab at 2-month intervals) were eventfree at 8 years.","journal-title":"J Clin Oncol"},{"issue":"19","key":"133_CR23","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","volume":"13","author":"M Taskinen","year":"2007","unstructured":"Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Lepp\u00e4 S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13(19):5784\u2013921. 1.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"133_CR24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","volume":"26","author":"D Canioni","year":"2008","unstructured":"Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008;26(3):440\u20136.","journal-title":"J Clin Oncol"},{"key":"133_CR25","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-11-0264","volume":"17","author":"BE Wahlin","year":"2011","unstructured":"\u2022\u2022 Wahlin BE, Sundstr\u00f6m C, Holte H, et al. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res. 2011;17:4136\u201344. The therapeutic effects of rituximab were augmented by T cells in the microenvironment (lymphnodes) and in blood. Both CD4(+) and CD8(+) cells were favorable in patients treated with rituximab and with addition of IFN-\u03b12a the negative impact of few CD8(+) cells was abrogated.","journal-title":"Clin Cancer Res"},{"key":"133_CR26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15:1110\u20137.","journal-title":"J Clin Oncol"},{"key":"133_CR27","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G Salles","year":"2008","unstructured":"Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112:4824\u201331.","journal-title":"Blood"},{"issue":"10","key":"133_CR28","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","volume":"23","author":"AZ Rohatiner","year":"2005","unstructured":"Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005;23(10):2215\u201323.","journal-title":"J Clin Oncol"},{"key":"133_CR29","first-page":"2644","volume":"6","author":"TA Davis","year":"2000","unstructured":"Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res. 2000;6:2644\u201352.","journal-title":"Clin Cancer Res"},{"key":"133_CR30","first-page":"951","volume":"86","author":"S Sacchi","year":"2001","unstructured":"Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin\u2019s lymphoma. Haematologica. 2001;86:951\u20138.","journal-title":"Haematologica"},{"key":"133_CR31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/10428190701704647","volume":"49","author":"E Kimby","year":"2008","unstructured":"Kimby E, Jurlander J, Geisler C, Nordic Lymphoma Group, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma. 2008;49:102\u201312.","journal-title":"Leuk Lymphoma"},{"key":"133_CR32","doi-asserted-by":"crossref","unstructured":"Kimby E, \u00d6stenstad B, de Nully Brown P, et al. Rituximab (R) in combination with interferon-\u03b12a (IFN) shows better response than single R in patients with follicular or other CD20+ low-grade (indolent) lymphoma. A randomized phase III study from the Nordic Lymphoma Group. Ann Oncol. ICML Lugano 2011; abstract #.","DOI":"10.1182\/blood.V120.21.794.794"},{"issue":"16","key":"133_CR33","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1200\/JCO.2007.13.7729","volume":"26","author":"G Cartron","year":"2008","unstructured":"Cartron G, Zhao-Yang L, Baudard M, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol. 2008;26(16):2725\u201331.","journal-title":"J Clin Oncol"},{"key":"133_CR34","unstructured":"Rossi JD, et al. Blood. 2011; ASH abstract 98:607A."},{"key":"133_CR35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","volume":"115","author":"N Bella Di","year":"2010","unstructured":"Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115:475\u201380.","journal-title":"Blood"},{"key":"133_CR36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1078-0432.CCR-08-2647","volume":"16","author":"OA O\u2019Connor","year":"2010","unstructured":"O\u2019Connor OA, Portlock C, Moskowitz C, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res. 2010;16:719\u201326.","journal-title":"Clin Cancer Res"},{"key":"133_CR37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00063030-200620010-00002","volume":"20","author":"L Paoluzzi","year":"2006","unstructured":"Paoluzzi L, O\u2019Connor OA. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs. 2006;20:13\u201323.","journal-title":"BioDrugs"},{"key":"133_CR38","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","volume":"12","author":"B Coiffier","year":"2011","unstructured":"\u2022 Coiffier B, Osmanov EA, Hong X, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011;12:773\u201384. This is the largest randomized trial on relapsed refractory follicular lymphoma and with the main end-point, PFS, statistically significant, however, not clinically important as median PFS was extended only from 11.0 to 12.8 months.","journal-title":"Lancet Oncol"},{"key":"133_CR39","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","volume":"27","author":"S Vos de","year":"2009","unstructured":"de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27:5023\u201330.","journal-title":"J Clin Oncol"},{"key":"133_CR40","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2010.08340.x","volume":"151","author":"A Agathocleous","year":"2010","unstructured":"Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol. 2010;151:346\u201353.","journal-title":"Br J Haematol"},{"issue":"21","key":"133_CR41","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","volume":"114","author":"AG Ramsay","year":"2009","unstructured":"\u2022\u2022 Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114(21):4713\u201320. A significant reduction in formation of the F-actin immune synapse was seen in tumor-infiltrating T cells from lymphoma patients compared with age-matched healthy donor cells. A repair of this defect was noted after treatment of both FL cells and T cells with the immunomodulatory drug lenalidomide.","journal-title":"Blood"},{"issue":"14","key":"133_CR42","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","volume":"14","author":"L Wu","year":"2008","unstructured":"Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14(14):4650.","journal-title":"Clin Cancer Res"},{"key":"133_CR43","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","volume":"27","author":"TE Witzig","year":"2009","unstructured":"Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s Lymphoma. J Clin Oncol. 2009;27:5404\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"133_CR44","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","volume":"11","author":"PL Zinzani","year":"2011","unstructured":"Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11(6):462\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"133_CR45","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2011.165","volume":"25","author":"GS Nowakowski","year":"2011","unstructured":"Nowakowski GS, LaPlant B, Habermann TM, et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011;25(12):1877\u201381.","journal-title":"Leukemia"},{"key":"133_CR46","doi-asserted-by":"crossref","unstructured":"Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol. 2012 Jun 1. E-pub.","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"133_CR47","unstructured":"Fowler N, Hagemeister F, McLaughlin P, et al. High response rates with lenalidomide plus rituximab for untreated indolent B cell non-Hodgkins Lymphoma. Ann Oncol ICML. 2011; Lugano abstract #137."},{"key":"133_CR48","doi-asserted-by":"crossref","unstructured":"Leonard J, Jung S, Johnson JL, et al. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. Abstracts of the 2012 Annual Meeting of the American Society of Clinical Oncology; June 1\u20135, 2012; Chicago, Illinois. Abstract 8000.","DOI":"10.1200\/JCO.2014.59.9258"},{"key":"133_CR49","unstructured":"Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open\u2010label, multicenter phase II trial. Swiss Group for Clinical Cancer Research (SAKK) in collaboration with the Nordic lymphoma group (NLG). ClinicalTrials.gov Identifier: NCT01307605."},{"key":"133_CR50","unstructured":"Kahl B, Byrd J, Flinn I, et al. Significant clinical activity of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3 kinase P110D, in patients with relapsed or refractory indolent and mantle cell lymphoma. Ann Oncol. 2011 Suppl 4 ICML; Lugano, abstract #350."},{"key":"133_CR51","doi-asserted-by":"crossref","unstructured":"Sven de Vos, Marshall T. Schreeder, Ian W. Flinn, Steven E. Coutre, John P Leonard. A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta Inhibitor, GS-1101 (CAL-101), in Combination with Rituximab and\/or Bendamustine in Patients with Relapsed or Refractory Indolent Non-Hodgkin\u2019s Lymphoma (iNHL). Abstracts of the 2011 Annual Meeting of the American Society of Hematology, San Diego, California #2699","DOI":"10.1182\/blood.V118.21.2699.2699"},{"key":"133_CR52","doi-asserted-by":"crossref","unstructured":"Winer ES, Ingham RR, Castillo JJ. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012;21(3):355\u201361.","DOI":"10.1517\/13543784.2012.656199"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0133-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-012-0133-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0133-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T15:43:35Z","timestamp":1594568615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-012-0133-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,16]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s11899-012-0133-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,16]]}}}